Table 3.
Key baseline laboratory data (treated set; n = 7034)
| HbA1c (%), mean (SD) |
8.1 (0.8) |
| HbA1c <8.5%, n (%) |
4811 (68) |
| Fasting plasma glucose (mmol/L), mean (SD) |
8.5 (2.4) |
| Body mass index (kg/m2), mean (SD) |
30.6 (5.3) |
| ≥ 35 kg/m2, n (%) |
1426 (20) |
| Weight (kg), mean (SD) |
86.4 (18.9) |
| Waist circumference (cm), mean (SD) |
105 (14) |
| Systolic/diastolic blood pressure (mmHg), mean (SD) |
135 (17)/77 (10) |
| Lipids (mmol/L), mean (SD) |
|
| Total cholesterol |
4.2 (1.1) |
| LDL-cholesterol |
2.2 (0.9) |
| HDL-cholesterol |
1.2 (0.3) |
| Triglycerides |
1.9 (1.4) |
| eGFR according to MDRD (mL/min/1.73 m2), mean (SD) |
74 (21) |
| eGFR according to MDRD (mL/min/1.73 m2), n (%) |
|
| ≥90 |
1534 (22) |
| 60 to <90 |
3671 (52) |
| 30 to <60 |
1796 (26) |
| ACR albumin ratio (mg/g), median (Q1, Q3) |
17.7 (7.1, 72.5) |
| ACR ratio (mg/g), n (%) |
|
| ≥ 30 – 300 |
2011 (29) |
| ≥ 300 | 771 (11) |
Results (based on a pre-final version of the database of this ongoing trial) may change slightly once trial is completed.